HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

KRMD

KORU Medical Systems, Inc.

Healthcare — Medical Instruments & Supplies

KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally. The company offers the FREEDOM infusion systems to deliver therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), secondary immunodeficiency disorder (SIDD), and paroxysmal nocturnal hemoglobinuria (PNH). Its products include the FREEDOM60 Syringe Driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company was formerly known as Repro Med Systems, Inc. and changed its name to KORU Medical Systems, Inc. in March 2022. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Mahwah, New Jersey.

None 5 analysts
$3.02
+$0.09 (+3.07%)
Target: $6.80 (125.2%)

Price History

52-Week Range
Sign in to add KRMD to a watchlist or set price alerts.

Fundamentals

Market Cap$202.11M
P/E Ratio (TTM)-
Forward P/E55.00
EPS (TTM)$-0.05
Dividend Yield-
Profit Margin-5.27%
Revenue Growth22.10%
ROE-13.70%
Debt/Equity19.89
Recommendation None
Analyst Target$6.80
Analysts5
Next Earnings Aug 5, 2026 AMC
Indexes -

Technical Indicators

RSI (14)65.0
Beta0.42
SMA 20-
SMA 40-
52-Week High$6.61
52-Week Low$2.91
50-Day Avg$4.06
200-Day Avg$4.57
Avg Volume201.8K
Volume183.8K

Performance Analysis

BULLISH

KRMD shows predominantly bullish signals based on its fundamentals and technicals.

+ Trading near its 52-week low ($2.91), which could present a value opportunity.
+ RSI at 65.0 shows positive momentum.
- Price is below both the 50-day and 200-day moving averages — in a downtrend.
+ Strong revenue growth of 22.1% year-over-year.
- Operating at a loss with -5.3% margin.
~ Wall Street consensus is "none" from 5 analysts.
+ Average analyst target of $6.80 implies 125.2% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:17 UTC

Back to Screener Export Report